OBJECTIVE: The purpose of this study was to compare patients with advanced-stage transitional cell carcinoma of the ovary with those who had poorly differentiated serous carcinoma for surgical response and survival. STUDY DESIGN: Sixty-two patients with transitional cell carcinoma were identified through a retrospective review and were matched with serous carcinoma patients for stage and residual disease. All patients received cisplatin-based chemotherapy. End points selected for analysis were surgical response, progression-free survival time, and survival time. Univariate and multivariate regression analyses were also performed. RESULTS: The surgical complete response rate for patients with transitional cell carcinoma was 37%, compared with 11% for those with serous carcinoma (p < 0.001). The survival time was significantly longer for the patients with transitional cell carcinoma (median 52.3 vs 22.0 months) (p < 0.001). Multivariate analyses strengthened these findings. CONCLUSION: Transitional cell carcinoma of the ovary is significantly more chemosensitive and associated with a better prognosis than the more common serous carcinoma.
OBJECTIVE: The purpose of this study was to compare patients with advanced-stage transitional cell carcinoma of the ovary with those who had poorly differentiated serous carcinoma for surgical response and survival. STUDY DESIGN: Sixty-two patients with transitional cell carcinoma were identified through a retrospective review and were matched with serous carcinomapatients for stage and residual disease. All patients received cisplatin-based chemotherapy. End points selected for analysis were surgical response, progression-free survival time, and survival time. Univariate and multivariate regression analyses were also performed. RESULTS: The surgical complete response rate for patients with transitional cell carcinoma was 37%, compared with 11% for those with serous carcinoma (p < 0.001). The survival time was significantly longer for the patients with transitional cell carcinoma (median 52.3 vs 22.0 months) (p < 0.001). Multivariate analyses strengthened these findings. CONCLUSION: Transitional cell carcinoma of the ovary is significantly more chemosensitive and associated with a better prognosis than the more common serous carcinoma.
Authors: Basile Tessier-Cloutier; Dawn R Cochrane; Anthony N Karnezis; Shane Colborne; Jamie Magrill; Aline Talhouk; Jonathan Zhang; Samuel Leung; Christopher S Hughes; Anna Piskorz; Angela S Cheng; Kendall Greening; Andreas du Bois; Jacobus Pfisterer; Robert A Soslow; Stefan Kommoss; James D Brenton; Gregg B Morin; C Blake Gilks; David G Huntsman; Friedrich Kommoss Journal: Hum Pathol Date: 2020-04-29 Impact factor: 3.466